Indivior Pharmaceuticals, Inc. 8-K

What Happened

• On April 30, 2026, Indivior Pharmaceuticals, Inc. announced and furnished a press release reporting its financial results for the period ended March 31, 2026 (Item 2.02).
• The company also posted presentation materials and an updated corporate presentation on its website the same day (Item 7.01). These materials were furnished as Exhibits 99.2 and 99.3 to the Form 8-K.
• The press release is furnished as Exhibit 99.1, and the filing includes the Inline XBRL cover page (Exhibit 104) (Item 9.01).

Key Details

• Press release reporting results for the period ended March 31, 2026 was issued and filed on April 30, 2026 (Exhibit 99.1).
• Presentation materials dated April 30, 2026 were posted to Indivior’s website and furnished as Exhibit 99.2.
• An updated corporate presentation was posted and furnished as Exhibit 99.3.
• Inline XBRL cover page (interactive data) included as Exhibit 104.

Why It Matters

• The 8-K provides the company’s latest quarterly earnings and related investor materials; shareholders and analysts should review the press release and presentations for revenue, profit/loss, and any commentary on business trends or guidance.
• Posting the materials under Regulation FD ensures the information was broadly disclosed to the market the same day.
• The filing does not report executive changes, mergers, or other material corporate actions beyond the earnings disclosure and updated presentations.